Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study
Consistent with the well-established profile of intravenous anifrolumab, subcutaneous anifrolumab demonstrated significant, clinically meaningful treatment benefits when added to standard therapy, and an acceptable safety profile in patients with moderate to severe SLE.
Authors
- Catharina Lindholm
- Jenny Wissmar
- Kenneth Kalunian (ORCID: https://orcid.org/0000-0003-0261-3102)
- Patricia Puzio
- E. Morand
- Richard Alan Furie (ORCID: https://orcid.org/0000-0001-6712-1585)
- Anca Askanase (ORCID: https://orcid.org/0000-0003-4597-5023)
- Emon Khan
- Susan Manzi
- Michael Song
- Yoshiya Tanaka
- The TULIP‐SC investigators
- Ian N. Bruce
Institutions
- Queen's University Belfast (GB)
- Northwell Health (US)
- Allegheny Health Network (US)
- University of Occupational and Environmental Health Japan (JP)
- Monash Medical Centre (AU)
- University of California System (US)
- University of Manchester (GB)
- NIHR Oxford Musculoskeletal Biomedical Research Centre (GB)
- AstraZeneca (Australia) (AU)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Spain) (ES)
- Monash University (AU)
- Columbia University (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1002/art.70041
- Citations
- 1
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 1.67
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Biogen
- National Institute for Health and Care Research
- Genentech
- EMD Serono
- Manchester Biomedical Research Centre